When should a PET scan be performed in a patient with non‑Hodgkin lymphoma who has completed lenalidomide therapy and received seven cycles of rituximab?

PET Scan Timing After Lenalidomide and Rituximab for Non-Hodgkin Lymphoma

Perform a PET scan immediately at the completion of all therapy (after the 7th cycle of rituximab) to define complete remission status, then follow with surveillance imaging at 6,12, and 24 months using CT scan only—routine surveillance PET scans are not recommended. 1

Post-Treatment Response Assessment

The most critical PET scan timing is at the end of treatment to establish baseline remission status:

• PET is highly recommended for post-treatment assessment to define complete remission according to revised response criteria 1, 2, 1
• This end-of-treatment PET should be performed after completing all planned therapy (in your case, after the 7th rituximab cycle)
• If PET shows positivity and therapeutic consequences are being considered, histological confirmation is strongly recommended before changing treatment 1

Important Caveat on Timing

Wait at least 8 weeks after any radiation therapy before performing PET-CT, as false-positives may occur from post-treatment changes 3. For rituximab-based therapy without radiation, the scan can be performed shortly after the final infusion, though some data suggest waiting several weeks may reduce false-positive findings 4.

Surveillance Strategy After Treatment

Routine surveillance PET scans are explicitly NOT recommended 1, 2, 1, 5. The evidence is clear on this point:

• CT scans at 6,12, and 24 months after end of treatment are the standard imaging approach 1
• There is no definitive evidence that routine imaging in patients in complete remission provides any outcome advantage 1
• The false-positive rate with surveillance PET scans exceeds 20%, leading to unnecessary investigations, radiation exposure, biopsies, expense, and patient anxiety 5

Clinical Follow-Up Schedule

Beyond imaging, the recommended surveillance includes 1:

• History and physical examination:

  • Every 3 months for year 1
  • Every 6 months for years 2-3
  • Annually thereafter

• Laboratory monitoring:

  • Blood count and LDH at 3,6,12, and 24 months
  • Then only as needed for suspicious symptoms

When to Consider Additional PET Imaging

PET scans during surveillance should be prompted by clinical indications only 5:

• Development of new symptoms suggesting relapse
• Suspicious findings on physical examination
• Rising LDH or other laboratory abnormalities
• Suspicious findings on routine CT surveillance

Special Consideration for High-Risk Patients

High-risk patients with curative options may potentially mandate more frequent controls 1, though this should still avoid routine PET surveillance and focus on clinical assessment with CT imaging.

Interim PET During Treatment

While your patient has completed therapy, it's worth noting that interim PET (after 1-4 cycles) should not lead to treatment changes outside of clinical trials 1, 2, 1. Studies show conflicting results on its predictive value, and it can lead to increased false-positives 3.

Key Pitfalls to Avoid

1. Do not order routine surveillance PET scans—this is explicitly discouraged by multiple guidelines and wastes resources while causing patient harm
2. Do not interpret mild residual uptake as disease—uptake less than or equal to mediastinal blood pool structures is considered negative 6
3. Do not rush the end-of-treatment PET—allow adequate time after therapy completion, especially if radiation was used
4. Do not change management based on PET findings alone—obtain histological confirmation if considering treatment modification for PET-positive findings 1